GLP-1 exendin-4 peptide analogs and uses thereof

Details GLP-1 exendin-4 peptide analogs and uses thereof GLP-1 exendin-4 peptide analogs and uses thereof

2002-07-30

2009-08-18

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S308000, C530S324000

Reexamination Certificate

active

07576050

ABSTRACT:
The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.

REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 6268479 (2001-07-01), Stern et al.
patent: 6429197 (2002-08-01), Collidge et al.
patent: 7157429 (2007-01-01), Bachovchin
patent: 2002/0115605 (2002-08-01), During et al.
patent: 2003/0004162 (2003-01-01), Treadway
patent: 2003/0050227 (2003-03-01), Kondo
patent: 2004/0018981 (2004-01-01), Dong
patent: 2005/0239854 (2005-10-01), Sugiyama
patent: 0658568 (1995-06-01), None
patent: 1304121 (2003-04-01), None
patent: WO 95/31214 (1995-11-01), None
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO99/038501 (1999-08-01), None
patent: WO 99/40788 (1999-08-01), None
patent: WO 99/43705 (1999-09-01), None
patent: WO99/46283 (1999-09-01), None
patent: WO99/67278 (1999-12-01), None
patent: WO 0016797 (2000-03-01), None
patent: WO 200016797 (2000-03-01), None
patent: WO 00/34332 (2000-06-01), None
patent: WO 00/41546 (2000-07-01), None
patent: WO00/47219 (2000-08-01), None
patent: WO 00/66142 (2000-11-01), None
patent: WO 00/73331 (2000-12-01), None
patent: WO 01/04156 (2001-01-01), None
patent: WO 01/51078 (2001-07-01), None
patent: WO 02/46227 (2002-06-01), None
Wang et al. ‘Glucagon-like Peptide-1 Can Reverse the Age-related Decline in Glucose Tolerance in Rats’ J. Clin. Invest. 1997 99: 2883-2889.
Oka et al. Endogenous GLP-1 is involved in [beta]-amyloid protein induced memory impairment and hippocampal neuronal death in rats.
Siram et al. Experimental Allergic Encephalomyelitis a Misleading Model of Multiple Sclerosis. Ann Neurol. vol. 58, pp. 939-945. 2005.
Citron, Martin. Alzheimer's Disease: Treatments in Discovery and Development. Nature Neurroscience Supplment. vol. 5, pp. 1055-1057. Nov. 2002.
File Medline on STN An No. 2005478947. Simmons, Zachary. “Management Strageies for Patients with Amyotrphoic Lateral Sclerosis from diagnosis Through Death.” The Neurologist (Sep. 2005), vol. 11, No. 5, pp. 257-270. Abstract only.
Azzouz, Mimoun “Gene Therapy for ALS: Progress and Prospects” Biochemical et Biophysica Acta (2006), vol. 1762 pp. 112-1127.
Margolis et al. ‘Diagonsis of Huntington Disease’ Clinical Chemistry, vol. 49, No. 10 pp. 1726-1732 (2003).
Korczyn et al. ‘Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease’ Drugs vol. 62, No. 5 pp. 775-786. 2002.
Steinman et al. ‘How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multple Sclerosis’ Ann Neurol. vol. 60, pp. 12-21. 2006.
Patel et al. Pharmacotherapy of Cognitive Impariment in Alzheimer's Disease: A Review J. Geriatr. Psychiatry Neruol. vol. 8 pp. 81-95. 1995.
Pinderhuges et al. Evidence-Based Apporach to Management of Feverin Patients With End-Stage Dementia. J. of Palliative Med. vol. 6, No. 3, 2003.
Okamoto et al. “Treatment of Vascular Dementia.” Ann. New York Academy of Science. pp. 507-512. 2002.
Poewe, W. “The Need for Neuroprotective Therapies in Parkinson's Disease.” Neurology. vol. 66 Supp. 4, pp. s2-s9.
Bressler et al., “Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus,”Arch. Int. Med. 157:836-848 (1997).
Calvo et al., “Structural characterization by affinity cross-linking of glucagon-like peptide-1 (7-36) amide receptor in rat brain,”J. Neurochem, 64(1):299-306 (1995).
Campos et al., “Divergent tissue-specific and developmental expression of receptors for glucagons and glucagon-like peptide-1 in the mouse,”Endocrinology134: 2156- 64 (1994).
Chen et al., “Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin-4 in the lizard,”J. Biol. Chem. 272: 4108-4115(1997).
De Ore et al., “The effect of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test,”J. Gernotol. 52: B245-249 (1997).
Drucker et al., “Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line,”Proc.Natl. Acad. Sci. 84: 3434-3438 (1987).
Egan et al. “Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-I1 adipocytes: one of several potential exrtapancreatic sites of GLP-1 action.”Endocrinology135: 2070-2075, 1994.
Elahi et al., “The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects,”Regul. Pep. 51: 63-74 (1994).
Elahi, et al. “The effect of age and glucose concentration on insulin secretion by the isolated perfused pancreas.”Endocrinology116; 11-16, 1985.
Federal Register 63, Friday, Feb. 20, 1998, p. 8652.
Fehmann et al. “Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-dependent Insulin Releasing polypeptide.”Endocrine Rev. 16:390-410, 1995.
Fehmann et al. “Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide,”Endocrine Rev. 16: 390-410 (1995).
Fehmann et al., “Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells,”Endocrinology130: 159-166 (1992).
Gefel et al. “Glucagon-Like Peptide I Analogs: Effects on Insulin Secretin and Adenosine 3′,5′-Monophosphate Formation.”Endocrinology126:2164-68, 1990.
Geula and Mesulam, “Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study,”Neuroscience33: 469-81 (1989).
Ghazzi et al., “Cardiac and glycemic benefits of troglitazone treatment in NIDDM,”Diabetes46: 433-439. (1997).
Göke et al., “Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites,”Eur. J. Neurosci: 2294-2300 (1995).
Göke et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide in an antagonist at the Glucagon-like Peprtide-1-(7-36)-amide receptor of insulin-secreting-β-cells,”J. Biol. Chem. 268: 19650-19655 (1993).
Greig et al., “Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.”Diabetologia42: 45-50 (1999).
Gromada et al. “Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic β-Cells by both Proximal and Distal Regulatory Steps in Stimullus-secretion Coupling.”Diabetes47:57-65, 1998.
Gutniak et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36 amide) in normal subjects and patients with diabetes mellitus,”N. Eng. J. Med. 326: 1316- 1322 (1992).
Guz et al. “Expression of murine STF-1, aputative insulin gene transcription factor, in β cells of pancreas, duodenal epithelium and pancreatic excrine and endocrine progenitors during ontogengy.”Development121: 11-18, 1995.
Hawes et al. “Distinct pathways of Gi-and Gα-mediated mitogen-activated protein kinase activation.”J. Biol. Chem. 270: 17148-17153, 1995.
Holz et al. “Activation of a cAMP-regulated Ca2+-signaling pathway in pancreatic beta-cells by the insulinotropic hormon

Affiliated with

Also associated with

Rating

GLP-1 exendin-4 peptide analogs and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GLP-1 exendin-4 peptide analogs and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GLP-1 exendin-4 peptide analogs and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4094601